Phoenestra develops an end-to-end approach for a broad range of stem cell-derived products:
Xeno-free induced pluripotent stem cell lines IPSC)
Telomerized MSC (TERT) lines (GMP-grade, licensed from Evercyte)
Bulk iPS cells and TERT/MSCs from controlled bioreactor cultivations
Extracellular Vesicle preparations from various cell lines / types
Engineered “universal” stem cell lines (in development)
iPS cell-derived (pre-)differentiated cells (in development)
Processed cells (in development)
Phoenestra is establishing GMP laboratories for GMP cell banking and manufacturing of (pre-)clinical study material
Based on these platform technologies, we are developing stem cell-derived therapeutic modalities (we are looking for partners) and offer R&D as well as GMP services.
Especially for vesicle-based products we are offering a One-stop-shop concept together wit our partner companies Evercyte (MSC/TERT lines, relevant bioassays) and TAmiRNA (RNA analytics, -omics, bioinformatics, biomarker developmet)
Privacy Policy and Imprint can be accessed by clicking "Contact us"
Company Details
- Employees
- 6
- Founded
- 2021
- Address
- Huemerstrasse 3-5, Linz,4020,austria
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.phoenestra.com
- HQ
- Linz
Phoenestra Gmbh Questions
Phoenestra Gmbh's website is https://www.phoenestra.com
Phoenestra Gmbh's LinkedIn profile is https://at.linkedin.com/company/phoenestra
Phoenestra Gmbh has
6 employees.
View email and phone details for 6
employees at Phoenestra Gmbh.
Phoenestra Gmbh's industry is
Biotechnology Research
Phoenestra Gmbh's top competitors are
Atlyphe Ag,
Gene Vector,
Oncoone,
Glyprovac,
A:head Bio Ag,
Proxygen,
Theriva Biologics, Inc.,
Fuse Vectors,
Serendip Innovations,
Heartbeat.bio Ag.
Phoenestra Gmbh's categories are Biotechnology Research
Phoenestra Gmbh's founding year is 2021
